Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Retained Earnings: 2022-2024

Historic Retained Earnings for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to -$1.1 billion.

  • Axsome Therapeutics' Retained Earnings fell 21.90% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 21.90%. This contributed to the annual value of -$1.1 billion for FY2024, which is 34.37% down from last year.
  • Per Axsome Therapeutics' latest filing, its Retained Earnings stood at -$1.1 billion for FY2024, which was down 34.37% from -$835.6 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Retained Earnings ranged from a high of -$596.3 million in FY2022 and a low of -$1.1 billion during FY2024.
  • Over the past 3 years, Axsome Therapeutics' median Retained Earnings value was -$835.6 million (recorded in 2023), while the average stood at -$851.6 million.
  • Data for Axsome Therapeutics' Retained Earnings shows a maximum YoY crashed of 40.12% (in 2023) over the last 5 years.
  • Over the past 3 years, Axsome Therapeutics' Retained Earnings (Yearly) stood at -$596.3 million in 2022, then tumbled by 40.12% to -$835.6 million in 2023, then crashed by 34.37% to -$1.1 billion in 2024.